Interview with the Innovators

At ASCO 2018, Oncology Practice Management (OPM) discussed the current state of genetics and genomic testing, the increasing understanding of biomarkers, and how they influence the treatment of patients with lung cancer. Read More ›

At ASCO 2018, Oncology Practice Management (OPM) spoke with Roy S. Herbst, MD, PhD, Chief of Medical Oncology and Associate Director for Translational Research at Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT, and David L. Rimm, MD, PhD, Professor of Pathology, Yale University School of Medicine, about the increasing role of biomarkers in the management of patients with lung cancer. Read More ›

Unclear Diagnoses in Patients with Metastatic Disease
Dr. Boccia addresses the problem of unclear diagnoses affecting approximately 15% of newly diagnosed patients with metastatic disease each year and the importance of an accurate diagnosis of tumor type in selecting the proper site-specific therapies. Read More ›

The bioT3 platform
Dr. Boccia describes the components of the bioT3 platform and its clinical utility in identifying tumor type and actionable targets for therapy. Read More ›

Clinical Validation of CancerTYPE ID
Dr. Boccia compares CancerTYPE ID to other gene expression tests and reviews studies validating its accuracy and clinical utility. Read More ›

CancerTYPE ID in the Clinic
Dr. Boccia describes cases in which he uses CancerTYPE ID in his clinical practice. Read More ›

CancerTREATMENT NGS+ in the Clinic
Dr. Boccia describes cases in which he uses CancerTREATMENT NGS+ in his clinical practice. Read More ›

Managing Costs in Oncology Care
Dr. Boccia talks about the importance of controlling costs in the current environment and how the bioT3 testing approach can help compared to other options. Read More ›


Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: